I-Mab
NASDAQ:IMAB
I-Mab
Net Income (Common)
I-Mab
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I-Mab
NASDAQ:IMAB
|
Net Income (Common)
-¥1.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-¥13.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
-¥1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
¥1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
¥8.5B
|
CAGR 3-Years
40%
|
CAGR 5-Years
47%
|
CAGR 10-Years
45%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Income (Common)
¥1.3B
|
CAGR 3-Years
61%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
See Also
What is I-Mab's Net Income (Common)?
Net Income (Common)
-1.5B
CNY
Based on the financial report for Dec 31, 2023, I-Mab's Net Income (Common) amounts to -1.5B CNY.
What is I-Mab's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-29%
Over the last year, the Net Income (Common) growth was 42%.